GLP-1 Generics India
4 articles on GLP-1 Generics India, written by Shotlee and medically reviewed for clinical accuracy.
Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
5 min read
IPM Growth Accelerates to 10.1% as GLP-1 Generics Reshape India's Anti-Diabet...
India's pharmaceutical market (IPM) surged 10.1% year-on-year in March 2026, with anti-diabetic therapies leading at 15.5% growth thanks to generic semaglutide entries. The GLP-1 agonist segment exploded to Rs 15.8 billion in MAT March, nearly tripling YoY. Ind-Ra forecasts sustained 9-10% IPM growth in FY27 amid chronic therapy dominance.
4 min read
India's Cheap GLP-1 Generics Risk Nutrition Gaps Amid Supplement Crisis
India's GLP-1 market surges with over 50 cheap generics from firms like Dr. Reddy's and Sun Pharma, priced as low as US$14/month post-patent expiry. Yet experts flag nutrition risks as appetite suppression drives reliance on substandard supplements failing label claims by 20-40%. Discover the quality crisis threatening diabetic and obese populations.
8 min read
Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
5 min read